ReviewPharmacological research2021
International policies and challenges on the legalization of traditional medicine/herbal medicines in the fight against COVID-19.
Review in Pharmacological research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Effect of a diet based on Iranian traditional medicine on inflammatory markers and clinical outcomes in COVID-19 patients: A double-blind, randomized, controlled trial.European journal of integrative medicine · 2022Trial
- Bioactive Profiling ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases.Frontiers in pharmacology · 2025Review
- Polysaccharides from Medicinal Plants: Bridging Ancestral Knowledge with Contemporary Science.Plants (Basel, Switzerland) · 2024Review
- Article
- The priority areas and possible pathways for health cooperation in BRICS countries.Global health research and policy · 2023Review
- Efficacy and Key Materials of East Asian Herbal Medicine Combined with Conventional Medicine on Inflammatory Skin Lesion in Patients withPharmaceuticals (Basel, Switzerland) · 2023Review
- Effect ofInternational journal of molecular and cellular medicine · 2023Article
- Characteristics and result reporting of registered COVID-19 clinical trials of Chinese and Indian traditional medicine: A comparative analysis.Frontiers in medicine · 2023Article
- The use of medicinal plants in the prevention of COVID-19 using the Health Belief Model: A survey based on the Iranian population.Journal of education and health promotion · 2023Article
- Article
- Therapeutic and palliative role of a Unani herbal decoction in COVID-19 and similar respiratory viral illnesses: Phytochemical & pharmacological perspective.Journal of ethnopharmacology · 2022Review
- TCM2COVID: A resource of anti-COVID-19 traditional Chinese medicine with effects and mechanisms.iMeta · 2022Article
- Complementary and alternative medicines use in COVID-19: A global perspective on practice, policy and research.Research in social & administrative pharmacy : RSAP · 2022Article
- Key quality factors for Chinese herbal medicines entering the EU market.Chinese medicine · 2022Review
- Prevalence and predictive factors of complementary medicine use during the first wave of the COVID-19 pandemic of 2020 in the Netherlands.BMC complementary medicine and therapies · 2022Article
- Development and Validation of a Tool to Improve Community Pharmacists' Surveillance Role in the Safe Dispensing of Herbal Supplements.Frontiers in pharmacology · 2022Article
- Potential common mechanism of four Chinese patent medicines recommended by diagnosis and treatment protocol for COVID-19 in medical observation period.Frontiers in medicine · 2022Article
- Characteristics of systematic reviews evaluating treatments for COVID-19 registered in PROSPERO.Epidemiology and infection · 2021Article
- Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma.International journal of nanomedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) has now rapidly spread around the world, causing an outbreak of acute infectious pneumonia. To develop effective and safe therapies for the prevention and treatment of COVID-19 has become the major global public health concern. Traditional medicine (TM)/herbal medicines (HMs) have been used to treat multiple epidemics in human history, which brings hope for the fight against COVID-19 in some areas. For example, in China, India, and South Korea with traditional medication history and theory, the governments issued a series of guidelines to support TM/HMs in the medication of COVID-19. In contrast, other countries e.g. North American and European governments are typically silent on these practices, unless to warn of possible harm and overselling. Such difference is due to the discrepancy in culture, history and philosophical views of health care and medication, as well as unharmonized policies and standards in the regulation and legalization of TM/HMs among different areas. Herein, we reviewed the responses and scientific researches from seven selected countries on the policies and legalization of TM/HMs to treat COVID-19, and also analyzed the major challenges and concerns to utilize the traditional knowledge and resource.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.